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The objective of this study was to investigate how a measure of educational and occupational attainment, a component of
cognitive reserve, modiﬁes the relationship between biomarkers of pathology and cognition in Alzheimer’s disease. The bio-
markers evaluated quantiﬁed neurodegeneration via atrophy on magnetic resonance images, neuronal injury via cerebral spinal
ﬂuid t-tau, brain amyloid-b load via cerebral spinal ﬂuid amyloid-b1–42 and vascular disease via white matter hyperintensities on
T2/proton density magnetic resonance images. We included 109 cognitively normal subjects, 192 amnestic patients with mild
cognitive impairment and 98 patients with Alzheimer’s disease, from the Alzheimer’s Disease Neuroimaging Initiative study,
who had undergone baseline lumbar puncture and magnetic resonance imaging. We combined patients with mild cognitive
impairment and Alzheimer’s disease in a group labelled ‘cognitively impaired’ subjects. Structural Abnormality Index scores,
which reﬂect the degree of Alzheimer’s disease-like anatomic features on magnetic resonance images, were computed for each
subject. We assessed Alzheimer’s Disease Assessment Scale (cognitive behaviour section) and mini-mental state examination
scores as measures of general cognition and Auditory–Verbal Learning Test delayed recall, Boston naming and Trails B scores as
measures of speciﬁc domains in both groups of subjects. The number of errors on the American National Adult Reading Test
was used as a measure of environmental enrichment provided by educational and occupational attainment, a component of
cognitive reserve. We found that in cognitively normal subjects, none of the biomarkers correlated with the measures of
cognition, whereas American National Adult Reading Test scores were signiﬁcantly correlated with Boston naming and
mini-mental state examination results. In cognitively impaired subjects, the American National Adult Reading Test and all
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this general conclusion were absence of correlation between cerebral spinal ﬂuid amyloid-b1–42 and Boston naming and Trails B.
In contrast, white matter hyperintensities were only correlated with Boston naming and Trails B results in the cognitively
impaired. When all subjects were included in a ﬂexible ordinal regression model that allowed for non-linear effects and inter-
actions, we found that the American National Adult Reading Test had an independent additive association such that better
performance was associated with better cognitive performance across the biomarker distribution. Our main conclusions
included: (i) that in cognitively normal subjects, the variability in cognitive performance is explained partly by the American
National Adult Reading Test and not by biomarkers of Alzheimer’s disease pathology; (ii) in cognitively impaired subjects, the
American National Adult Reading Test, biomarkers of neuronal pathology (structural magnetic resonance imaging and cerebral
spinal ﬂuid t-tau) and amyloid load (cerebral spinal ﬂuid amyloid-b1–42) all independently explain variability in general cognitive
performance; and (iii) that the association between cognition and the American National Adult Reading Test was found to be
additive rather than to interact with biomarkers of Alzheimer’s disease pathology.
Keywords: Alzheimer’s disease; mild cognitive impairment; CSF biomarkers; MRI; cognitive reserve
Abbreviations: ADAS-Cog = Alzheimer’s disease Assessment Scale (Cognitive Behaviour Section); AMNART = American National
Adult Reading Test; MMSE = Mini-Mental State Examination
Introduction
Subjects with Alzheimer’s disease at autopsy typically were de-
mented in life. However, careful autopsy studies consistently
reveal an important clinical–pathological discordance. Up to 30%
of subjects who were cognitively normal in life are found at aut-
opsy to have a pathological proﬁle, typically dominated by amyl-
oid plaques, consistent with a diagnosis of Alzheimer’s disease
(Katzman et al., 1988; Crystal et al., 1993; Hulette et al., 1998;
Price and Morris, 1999; Schmitt et al., 2000; Morris and Price,
2001; Riley et al., 2002; Knopman et al., 2003). Understanding
this disassociation between cognition and pathology is important
for the success of preventive strategies targeted at neuropathology
in the non-demented elderly as well as relevant for improving our
understanding of the disease. The concept of cognitive reserve
(Stern, 2009) is increasingly employed to explain this disassoci-
ation. This theory posits that subjects with higher cognitive reserve
have a greater capacity to cope with pathological insults than
those with low cognitive reserve, and these individual differences
in reserve mechanisms help explain why cognitive decline may be
initiated at different times in relation to the onset of pathology.
This concept can also be expressed as the difference between the
predicted and the observed cognitive performance of an individual
for a given level of brain pathology (Reed et al., 2010). Figure 1
illustrates the question we are addressing—how does cognitive
reserve modify the impact of pathology on cognition? In this art-
icle, we investigate one aspect of cognitive reserve as measured by
the number of errors on the American National Adult Reading Test
(AMNART), an indicator of pre-morbid verbal intelligence. While
AMNART does not capture all the components that contribute to
cognitive reserve, it is a measure of the level of environmental
enrichment provided by educational and occupational attainment
and has been shown to correlate with IQ (Ryan and Paolo, 1992).
Dementia is a multi-factorial disease wherein cumulative patho-
logical brain insults (usually more than one pathology) result in
progressive cognitive decline, which ultimately leads to dementia.
Amyloid plaques and neuroﬁbrillary tangles are the
well-established pathological hallmarks of Alzheimer’s disease.
The other main pathological processes in Alzheimer’s disease are
inﬂammation and neurodegeneration, which is due to the loss of
neurons, synapses and dendritic de-arborization that occurs on a
microscopic level. In this article, we restrict ourselves to the pri-
mary pathologies of Alzheimer’s disease as well as to ischaemic
cerebrovascular disease since it is the most common secondary
pathological process seen among demented subjects with
Alzheimer’s disease pathology at autopsy (Snowdon et al., 1997;
White et al., 2005; Schneider et al., 2009). We use MRI and CSF
biomarkers to quantify each of these pathological changes. Low
CSF amyloid-b1–42 reﬂects deposition of amyloid-b in plaques
(Strozyk et al., 2003; Tapiola et al., 2009). High CSF t-tau levels
reﬂect active axonal and neuronal damage (Blennow et al., 1995).
Atrophy seen on MRI is the macroscopic result of loss of neurons,
synapses and dendritic arborization (Bobinski et al., 2000). We use
the Structural Abnormality Index score as an indicator of the se-
verity of the Alzheimer’s disease-like pattern of atrophy on struc-
tural MRI. Structural Abnormality Index scores were developed to
condense the severity and location of Alzheimer’s disease-related
atrophy on the 3D MRI scan into a single number (Vemuri et al.,
2008). White matter hyperintensity (or leukoaraiosis) on
ﬂuid-attenuation inversion recovery MRI in elderly subjects is sus-
pected to be a direct manifestation of microvascular ischaemic
injury. We use white matter hyperintensity load as an indicator
of severity of small vessel disease.
Several recent studies have used biomarkers to understand the
effect of cognitive reserve on the relationship between pathology
and cognition (Stern, 2009). These studies have examined the
effect of cognitive reserve on cross-sectional measures of amyloid
load (Kemppainen et al., 2008; Roe et al., 2008a; Rentz et al.,
2010; Dumurgier et al., 2010), neurodegeneration (Querbes et al.,
2009; Piras et al., 2010), ﬁbre tract integrity (Teipel et al., 2009),
white matter hyperintensity (Brickman et al., 2009b), cerebral me-
tabolism (Alexander et al., 1997; Scarmeas et al., 2003; Perneczky
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et al., 2009) and perfusion (Liao et al., 2005) independently.
Autopsy studies have shown the association of plaques and tan-
gles with cognitive reserve (Bennett et al., 2003; Boyle et al.,
2008; Koepsell et al., 2008; Roe et al., 2008b). However, we
know of no in vivo studies that have investigated the effect of
cognitive reserve on all the primary pathologies seen in
Alzheimer’s disease including neurodegeneration and the most
common secondary pathology (i.e. vascular disease) in the same
cohort of subjects that spans the cognitive spectrum from normal
to mild Alzheimer’s disease.
The main aim of our article is to investigate how the component
of cognitive reserve measured by AMNART modiﬁes the relation-
ship between biomarkers of pathology and cognition in
Alzheimer’s disease by answering these two questions: (i) does
AMNART explain variability in cognitive measures, even after ad-
justing for biomarkers of pathology within cognitively normal and
impaired subjects?; and (ii) does AMNART have an additive asso-
ciation with cognition or does it interact with biomarkers of
pathology?
Materials and methods
The data used in this study are from the Alzheimer’s Disease
Neuroimaging Initiative, a longitudinal multicentre observational
study of elderly individuals with normal cognition, amnestic mild cog-
nitive impairment and Alzheimer’s disease collected from 59 participat-
ing institutes (Jack et al., 2008). Written informed consent was
obtained for participation in these studies, as approved by the
Institutional Review Board at each of the participating centres. The
details of the Alzheimer’s Disease Neuroimaging Initiative can be
found at http://www.ADNI-info.org.
Clinical and cognitive assessment
The total sample in this article consists of 399 subjects (109 cognitively
normal, 192 amnestic mild cognitive impairment, 98 Alzheimer’s dis-
ease) who had CSF biomarker data at baseline (CSF was obtained at
baseline in 51% of the Alzheimer’s Disease Neuroimaging Initiative
cohort). Baseline clinical diagnosis and cognitive assessments of all
three clinical groups and clinical/cognitive assessment scores were con-
sidered in this study. AMNART was obtained in each of the individuals
(Ryan and Paolo, 1992) and the number of errors on AMNART was
used as a measure of cognitive reserve in this study. The AMNART
evaluates pre-morbid verbal IQ in individuals and is determined by the
number of errors made on a pronunciation list of 50 irregularly spelled
words such as ‘ache’, ‘debt’ and ‘bouquet’. Alternative proxies of cog-
nitive reserve exist, such as education, but we chose AMNART since it
is more sensitive and shows greater variation than education (Rentz
et al., 2010). While the Alzheimer’s Disease Neuroimaging Initiative
generally classiﬁes subjects as cognitively normal, having mild cognitive
impairment, or Alzheimer’s disease, for this study, we combined sub-
jects who had mild cognitive impairment and Alzheimer’s disease at
baseline into a single impaired group since the distribution of AMNART
was very similar in amnestic-mild cognitive impairment and
Alzheimer’s disease. In this way, the impaired group represents a
broad spectrum of cognitive impairment and also shows a greater
dynamic range of values on standard cognitive tests.
We used Alzheimer’s Disease Assessment Scale—Cognitive
Behaviour Section (ADAS-Cog; Rosen et al., 1984) and Mini-Mental
State Examination (MMSE; Folstein et al., 1975) as overall indices of
general cognitive performance. In this study, we used the modiﬁed
ADAS-Cog score (ADAS-Cog-13) from the Alzheimer’s Disease
Neuroimaging Initiative, which has two additional components
(delayed recall task and a number cancellation task). Additionally,
we used domain-speciﬁc scores—Auditory–Verbal Learning Test-
delayed recall (Rey, 1964) as a measure of memory encoding,
Boston naming (Kaplan et al., 1983) to test language functioning
and Trails B (US War Department, 1944) as a measure of executive
function. We analysed all tests in all subjects.
Cerebral spinal ﬂuid methods and
processing
CSF was collected at each site, transferred into polypropylene transfer
tubes, frozen on dry ice within 1h after collection and shipped over-
night to the Alzheimer’s Disease Neuroimaging Initiative Biomarker
Core laboratory at the University of Pennsylvania Medical Centre on
dry ice. When samples were received in the Laboratory, they were
thawed and aliquots were stored in bar coded polypropylene vials at
80C. A standardized protocol was implemented to quantify bio-
marker concentrations in each of the CSF Alzheimer’s Disease
Neuroimaging Initiative baseline aliquots using a multiplex xMAP
Luminex platform (Luminex Corp) with Innogenetics (INNO-BIA
AlzBio3, for research use only reagents) immunoassay kit-based re-
agents, a protocol which has been tested and validated
(Vanderstichele, 2008; Shaw et al., 2009). Quality control values ob-
tained during the analyses of Alzheimer’s Disease Neuroimaging
Initiative baseline CSF aliquots were: inter-day reproducibilities
(%CV) for an Alzheimer’s disease CSF pool and a routine clinic
patient CSF pool of 4.5% and 6.4% for t-tau and 3.3% and 6.9%
Figure 1 Illustration of where cognitive reserve acts along the pathology–cognitive decline cascade. Ab = amyloid-b;
AVLT = Auditory–Verbal Learning Test; WMH = white matter hyperintensity volume.
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2 values for comparison of retested samples were
0.98 and 0.90. Baseline CSF values were considered in this study.
Magnetic resonance imaging methods
and preprocessing
The 1.5T MRI scans from the Alzheimer’s Disease Neuroimaging
Initiative were used for this study. The nominal parameters of the
morphometric T1-weighted magnetization prepared rapid acquisition
gradient echo imaging sequence and T2-weighted MRI scans can be
found in Jack et al. (2008). The T1 MRI images are corrected for
gradient non-linearity and intensity inhomogeneity (Jack et al., 2008)
using a centralized MRI-processing pipeline at the Mayo Clinic,
Rochester. Structural Abnormality Index-scores were estimated on
these preprocessed images and are described in the online
Supplementary Material. The T2/PD and T1-weighted images were
used to estimate the white matter hyperintensity load based on the
method presented in (Schwarz et al., 2009) (http://www.ncbi.nlm.nih
.gov/pmc/articles/PMC2864489/).
Statistical analysis
Correlations between American National Adult Reading
Test, biomarkers and cognition
We estimated the association between variables using partial
Spearman rank-order correlation, which we denote by ‘partial rs’. All
correlations adjust for, or partial out, the effects of age and gender.
We also report partial correlations after further adjusting for bio-
marker or AMNART. Rank-order correlations were used because of
skewness and otherwise non-normal distributions resulting from ﬂoor
or ceiling effects. Partial correlations were calculated using SAS version
9.1.3.
An important goal of this study was to characterize how mean cog-
nition changes with AMNART and biomarker levels and to assess
whether the possibly protective effect of cognitive reserve is additive,
whereby it is relatively constant across levels of neuropathology,
or whether there is an interaction in which the protective effect of
cognitive reserve depends on the level of the biomarker as would be
the case, for example, if cognitive reserve offered protection only at
mild levels of neuropathology. To address these questions, we used
proportional odds ordinal logistic regression models (Harrell, 2001)
treating the cognitive test as an ordinal response. These models gen-
eralize binary logistic regression to the case where there are more than
two categories but they have a natural ordering. One interpretation
of these models is that they treat the observed score on a cogni-
tive test as a discrete or ‘coarsened’ estimate of an unobservable, or
latent, cognitive quantity that falls along a true continuum that
is assumed to have an underlying continuous logistic distribution. As
binary logistic regression can provide the estimated probability of
an event or non-event as a function of covariates, proportional odds
logistic regression models can be used to estimate the probability
of each level of the ordinal response, e.g. MMSE = 30, 29, 28, etc.
We then calculate the estimated mean value for the cognitive test as
a function of covariates by summing up the scores multiplied by
their probabilities (Hannah and Quigley, 1996). For example, if a
test took on values 1, 2 or 3, and the estimated probabilities
were 0.20, 0.30 and 0.50, the mean would be
1(0.20) + 2(0.30) + 3(0.50) = 2.3. With this approach to estimating
the mean in an ordinal logistic regression model, we avoid the
problems of using linear regression when there are strong ﬂoor or
ceiling effects or a large number of ties.
To reduce skewness, we transformed AMNART by taking the square
root and took the base 2 logarithm of amyloid-b1–42, t-tau, and white
matter hyperintensity volume. So as not to assume strictly linear rela-
tionships, in all models we ﬁt the biomarker and AMNART predictors
as restricted cubic splines with knots at the 10th, 50th and 90th per-
centiles (Harrell, 2001). To assess the extent to which the relationship
between AMNART and cognition varied by pathology level, we
included a linear interaction, or product term, whereby the AMNART
score was multiplied by the pathology measure (Harrell, 2001). To
adjust for possible age effects and sex effects in the MMSE models
we included age, sex, an age by sex interaction, and allowed age and
sex to interact with the linear components of the biomarker and
AMNART terms.
In all, the full models for MMSE had 18 degrees of freedom. While
models of this complexity are reasonable given the large sample size,
in order to obtain more stable and smoother estimates, we used a
ridge-regression penalization approach with the penalty factor
chosen to optimize the ‘corrected Akaike Information Criterion’
(Harrell, 2001). For the MMSE, the penalization reduced the effective
degrees of freedom for the amyloid-b1–42 model to 6.3 degrees of
freedom, the Structural Abnormality Index model to 9.2 degrees of
freedom, the t-tau model to 7.3 degrees of freedom and the white
matter hyperintensity model to 6.6 degrees of freedom. We used
large-sample Wald tests on the full model to assess: (i) the interaction
between biomarker and AMNART; (ii) the biomarker effect controlling
for age, sex and AMNART; and (iii) the AMNART effect controlling for
age, sex and biomarker. Ordinal regression modelling was performed
using Harrell’s Design package and R version 2.8.1 (R Development
Core Team, 2008).
To explore the effects of measurement error in AMNART and bio-
markers on our ordinal regression model estimates, we performed a
sensitivity analysis using the simulation-extrapolation method (Cook
and Stefanski, 1994). The idea behind this approach is to add meas-
urement error to the predictors and then re-estimate the regression
coefﬁcients. By adding increasing amounts of measurement error, for a
given regression coefﬁcient, one can plot the resulting estimate on the
y-axis and the amount of measurement error on the x-axis and then ﬁt
a trend line to these observations. One then extrapolates from this
trend line the value of the regression coefﬁcient assuming zero meas-
urement error. We performed the simulation-extrapolation method
ﬁve times by assuming measurement error was such that the
intra-class correlation coefﬁcient for AMNART and the biomarkers
was 0.50, 0.60, 0.70, 0.80 and 0.90.
Results
Patient characteristics
The demographics, clinical summary, biomarker characteristics of
cognitively normal, cognitively impaired subjects (amnestic mild
cognitive impairment and Alzheimer’s disease) are shown in
Table 1. Figure 2 shows the distribution of AMNART scores sep-
arately for cognitively normal, amnestic mild cognitive impairment
and Alzheimer’s disease. Based on the Wilcoxon rank-sum/Mann–
Whitney U-test, the number of errors was signiﬁcantly lower for
the cognitively normal group than amnestic mild cognitive
1482 | Brain 2011: 134; 1479–1492 P. Vemuri et al.impairment (area under receiver operating characteristic
curve = 0.64, P50.001) or Alzheimer’s disease (area under re-
ceiver operating characteristic curve = 0.67, P50.001) while
amnestic mild cognitive impairment and Alzheimer’s disease
were not different (area under receiver operating characteristic
curve = 0.52, P = 0.53).
Correlations between American
National Adult Reading Test,
biomarkers and cognition
Cognitively normal subjects
Among cognitively normal subjects, we found that none of the
biomarkers (CSF amyloid-b1–42, CSF t-tau, Structural Abnormality
Index or white matter hyperintensity volume) correlated with the
measures of cognition we assessed with all correlations 50.17 in
absolute value (P40.05). In contrast AMNART correlated with
MMSE (age and gender adjusted partial rs = 0.37, P50.01)
and Boston naming (age and gender adjusted partial rs = 0.31,
P50.01) but did not correlate with ADAS-Cog, Auditory–Verbal
Learning Test or Trails B (P40.05). The magnitude of the correl-
ation between MMSE and AMNART was similar (partial
rs = 0.37 to 0.36, P50.01) after adjusting for each of the
CSF and MRI biomarkers individually, as well as when all biomark-
ers of pathology where combined (partial rs = 0.36, P50.01).
Similarly the correlation between Boston naming and AMNART
were similar before and after adjusting for each of the CSF and
MRI biomarkers individually as well as when all were combined.
These correlations are illustrated in Table 2.
Cognitively impaired subjects
Among impaired subjects, the biomarkers of Alzheimer’s disease
(CSF amyloid-b1–42, CSF t-tau and MRI) correlated with the meas-
ures of general cognitive performance (ADAS-Cog, MMSE; age-
and gender-adjusted absolute partial rs = 0.19–0.51, P50.01).
These correlations were little changed after further adjusting for
AMNART (absolute partial rs = 0.17–0.51, P50.01). Most of the
Alzheimer’s disease biomarkers correlated with the domain scores
(Auditory–Verbal Learning Test, Boston naming, Trails B). The ex-
ception was absence of correlation between CSF amyloid-b1–42
with Boston naming and Trails B. These correlations were little
changed as well after adjusting for AMNART. White matter
Table 1 Patient characteristics at baseline
Cognitively
normal (n = 109)
Cognitively
impaired (n = 290)
Gender: female, n (%) 52 (48) 105 (36)
Apolipoprotein E "4 carriers, n (%) 27 (25) 172 (59)
Age, median (IQR), years 76 (72–78) 75 (70–80)
Education, median (IQR), years 16 (14–18) 16 (13–18)
Amyloid-b1–42, median (IQR), pg/ml 221 (154–248) 143 (127–169)
t-tau, median (IQR), pg/ml 63 (47–87) 96 (68–135)
Structural Abnormality Index, median (IQR) 0.9 (1.5 to 0.4) 0.2 (0.5 to 0.9)
White matter hyperintensity volume, median (IQR), cm
3 0.2 (0.1–0.5) 0.3 (0.1–0.8)
AMNART, median (IQR) 8 (4–15) 14 (7–21)
MMSE, median (IQR) 29 (29–30) 26 (24–28)
ADAS-Cog, median (IQR) 9.7 (6.3–13.0) 21.7 (16.7–27.3)
CDR-SB, median (IQR) 0.0 (0.0–0.0) 2.0 (1.0–3.5)
Auditory–Verbal Learning Test delayed recall, median (IQR) 7 (5–10) 1 (0–3)
Boston Naming, median (IQR) 28 (26–30) 26 (23–28)
CDR-SB = Clinical Dementia Rating ‘sum of boxes’; IQR = interquartile range deﬁned as (25th percentile, 75th percentile).
Figure 2 Box plots of the distribution of AMNART errors by
clinical group. The horizontal lines within each box represent the
25, 50 and 75th percentiles. The vertical lines extend out to the
furthest point within 1.5 interquartile ranges of the box, where
an interquartile range is the 75th minus the 25th percentiles.
AD = Alzheimer’s disease; CN = cognitively normal; MCI = mild
cognitive impairment.
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Auditory–Verbal Learning Test, but did correlate with domains
measures for language (Boston naming) and executive function
(Trails B).
AMNART correlated with ADAS-Cog (age and gender adjusted
partial rs = 0.14, P = 0.02), MMSE (age and gender adjusted par-
tial rs = 0.21, P50.01), Boston naming (age and gender ad-
justed partial rs = 0.37, P50.01) and Trails B (age and gender
adjusted partial rs = 0.22, P50.01). After further adjusting for
each of the CSF and MRI biomarkers, the magnitude of correlation
of AMNART with cognitive measures was similar irrespective of
the biomarker adjusted for. This correlation was also similar after
adjusting for all the biomarkers. These correlations are illustrated in
Table 3. As can be observed from the table, the correlation of
AMNART with the cognitive measures does not change after ad-
justment by any of the biomarkers. Also, there was no apparent
relationship between AMNART and biomarker among impaired
subjects, suggesting AMNART, amyloid-b1–42, t-tau and
Structural Abnormality Index are independent predictors of cogni-
tive performance.
Effect of American National Adult
Reading Test on the relationship
between biomarkers and cognition
We illustrate the interrelationship between MMSE, biomarker and
AMNART in Fig. 3. In each panel, we show MMSE as a function
of the biomarker level and show the estimated mean MMSE for
three levels of AMNART. We found that MMSE depended signiﬁ-
cantly on amyloid-b1–42 (P50.001), Structural Abnormality Index
(P50.001) and t-tau (P50.001) but not white matter hyperin-
tensity volume (P = 0.88). In all models, the effect of AMNART on
the relationship between MMSE and biomarker level was highly
signiﬁcant (P50.001). In other words, for a given level of cog-
nition, fewer errors on AMNART, i.e. higher cognitive reserve, is
associated with higher levels of t-tau, lower levels of CSF
amyloid-b1–42 and greater cerebral atrophy when compared with
subjects with low cognitive reserve.
For log CSF amyloid-b1–42 (Fig. 3A) there is an upward, but
possibly non-linear, trend indicating higher levels of amyloid-b1–
42 are associated with better performance on MMSE. Figure 3B
shows a clear, approximately linear, downward trend in MMSE as
Structural Abnormality Index increases while for any given level of
Structural Abnormality Index worse AMNART results in lower
average MMSE. For log t-tau, the association with MMSE appears
approximately linear. For log white matter hyperintensity, no sig-
niﬁcant association with MMSE was observed, while the additive
effect of AMNART was pronounced. We found no evidence of an
interaction between AMNART and the marker (P40.59 for each
marker) and infer that there is an approximate ‘additive’ associ-
ation such that for a given level of the biomarker, better perform-
ance on AMNART corresponds with an upward shift in average
MMSE. In contrast, an interaction between AMNART and bio-
marker would have resulted in signiﬁcantly different slopes for
the different AMNART groups in the regression of MMSE on bio-
markers (Fig. 3), which was not found.
In our sensitivity analysis evaluating the effects of measurement
error in AMNART or the biomarkers, we found that increasing
amounts of measurement error tended to attenuate observed
associations but that our estimates, as summarized graphically in
Table 2 Partial Spearman rank correlations for the cognitively normal patients
Predictor Adjustment variables
a Cognitive measurement
ADAS-Cog MMSE Auditory–Verbal
Learning Test
Boston Naming Trails B
Predictor variable
Amyloid-b1–42 0.14 0.14 0.04 0.12 0.11
STAND 0.07 0.01 0.04 0.16 0.04
t-tau 0.06 0.05 0.01 0.03 0.14
WMH 0.17 0.14 0.04 0.04 0.04
AMNART 0.16 0.37** 0.05 0.31** 0.07
AMNART adjusted for biomarkers
AMNART Amyloid-b1–42 0.17 0.36** 0.06 0.32** 0.08
AMNART STAND 0.16 0.37** 0.05 0.31** 0.07
AMNART t-tau 0.16 0.37** 0.05 0.31** 0.06
AMNART WMH 0.17 0.36** 0.05 0.32** 0.07
AMNART Amyloid-b1–42, t-tau,
STAND and WMH
0.18 0.36** 0.06 0.34** 0.07
Biomarkers adjusted for AMNART
Amyloid-b1–42 0.15 0.13 0.05 0.15 0.11
STAND 0.07 0.00 0.04 0.17 0.04
t-tau 0.05 0.06 0.00 0.02 0.14
WMH 0.18 0.12 0.04 0.03 0.03
a Age and gender are included.
STAND = Structural Abnormality Index; WMH = white matter hyperintensity.
*P-value between 0.01 and 0.05.
**P-value50.01.
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simulation-extrapolation method.
Discussion
The concept of cognitive reserve is being employed increasingly to
explain the difference between observed and expected cognitive
performance for a given degree of Alzheimer’s disease pathology.
We investigated the contribution of cognitive reserve on this dis-
association using biomarkers that capture two major aspects of
Alzheimer’s disease pathology (amyloid and neuronal) as well as
vascular pathology, which is very common among the elderly
population. The major ﬁndings from this study are: (i) that in
cognitively normal subjects, the variability in cognition is explained
partly by AMNART but not by biomarkers of Alzheimer’s disease
pathology; (ii) in cognitively impaired subjects, AMNART, bio-
markers of neuronal pathology (structural MRI and CSF t-tau)
and amyloid load (CSF amyloid-b1–42) were all independently
associated with cognitive and functional performance; and (iii)
that the association between cognition and AMNART was found
to be additive rather than to depend on biomarkers of Alzheimer’s
disease pathology such that better performance on AMNART cor-
responded with better cognition across the Alzheimer’s disease
continuum.
Cognitive reserve and cognition
The concept of reserve stemmed from the observation that there
is often poor one-to-one correspondence between the presence of
pathology at autopsy and cognition in life (Katzman et al., 1988).
Cognitive reserve is an inclusive term that has been loosely used to
explain the inter-subject variability in cognitive performance in the
face of brain pathology. There are several processes that constitute
cognitive reserve including genetic and environmental inﬂuences,
number of neurons and synapses, the sensitivity of neurons and
glia to pathology, neuroplasticity etc. Stern (2006) formally cate-
gorized cognitive reserve mechanisms into two parts: active and
passive. Passive cognitive reserve is created by pre-existing net-
works that are more efﬁcient or have greater capacity, and thus
may be less susceptible to disruption by pathology. Active cogni-
tive reserve is created by alternate networks that compensate for
pathological disruption of pre-existing networks. AMNART, which
measures pre-morbid verbal intelligence, may possibly capture
components from both of these cognitive reserve mechanisms.
In cognitively normal subjects we found that AMNART corre-
lated moderately with Boston naming (partial rs = 0.31,
P50.01) and MMSE (partial rs = 0.37, P50.01). This might
be expected since AMNART and Boston naming are both verbal
semantic knowledge tasks and MMSE has been shown to be cor-
related with education (Schmand et al., 1995). In cognitively
normal subjects, AMNART acts as a measure of verbal ability
and was found to be correlated with education. In cognitively
impaired subjects, we found that AMNART explained variability
in MMSE (P50.01), ADAS-Cog (P = 0.02), Boston naming
(P50.05) and Trails B (P50.05). These results support the
notion that AMNART explains inter-subject variation in the cogni-
tive response to brain pathology in cognitively impaired.
Biomarkers and cognition
In cognitively normal subjects, we did not ﬁnd signiﬁcant correl-
ations between any of the biomarkers and the cognitive measures
Table 3 Partial Spearman rank correlations for the cognitively impaired patients
Predictor Adjustment variables
a Cognitive measurement
ADAS-Cog MMSE Auditory–Verbal
Learning Test
Boston Naming Trails B
Predictor variable
Amyloid-b1-42 0.27** 0.19** 0.21** 0.00 0.09
STAND 0.51** 0.35** 0.27** 0.29** 0.33**
t-tau 0.22** 0.19** 0.23** 0.12* 0.14*
WMH 0.11 0.06 0.05 0.15* 0.23**
AMNART 0.14* 0.21** 0.03 0.37** 0.22**
AMNART adjusted for biomarkers
AMNART Amyloid-b1-42 0.16** 0.22** 0.04 0.37** 0.23**
AMNART STAND 0.14* 0.20** 0.02 0.37** 0.22**
AMNART t-tau 0.14* 0.20** 0.02 0.37** 0.22**
AMNART WMH 0.15* 0.21** 0.04 0.37** 0.22**
AMNART Amyloid-b1-42, t-tau,
STAND and WMH
0.16** 0.21** 0.02 0.37** 0.21**
Biomarkers adjusted for AMNART
Amyloid-b1-42 0.28** 0.20** 0.21** 0.02 0.10
STAND 0.51** 0.35** 0.26** 0.29** 0.33**
t-tau 0.22** 0.17** 0.22** 0.12 0.14*
WMH 0.10 0.04 0.05 0.13* 0.21**
a Age and gender are included.
STAND = Structural Abnormality Index; WMH = white matter hyperintensity.
*P value between 0.01 and 0.05.
**P value50.01.
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Boston Naming). Approximately one-third of elderly cognitively
normal subjects have amyloid pathology (Katzman et al., 1988;
Crystal et al., 1993; Hulette et al., 1998; Price and Morris, 1999;
Schmitt et al., 2000; Morris and Price, 2001; Riley et al., 2002;
Knopman et al., 2003). Amyloid deposition is believed to occur
early in the disease process and does not directly cause clinical
symptoms (Jack et al., 2009; Mormino et al., 2009). We, there-
fore, did not expect to ﬁnd a strong correlation between CSF
amyloid-b1–42 and cognition. On the other hand, neuroﬁbrillary
tangles and neurodegeneration are believed to be downstream
pathological events that progressively worsen in the presence of
a relatively static total load of amyloid and which lead directly to
cognitive impairment (Ingelsson et al., 2004; Jack et al., 2010).
The absence of substantial neurodegenerative pathology in the
cognitively normal subjects explains the absence of a strong cor-
relation between biomarkers of neuronal pathology and cognition
in these subjects. The literature on the lack of correlation between
biomarkers of amyloid load and cognition in the cognitively
normal is, however, not consistently unanimous. While some stu-
dies have found a poor correlation between amyloid load and
cognition in cognitively normal subjects (Aizenstein et al., 2008;
Jack et al., 2009; Vemuri et al., 2010) others have found signiﬁ-
cant correlations between amyloid load and cognition (Pike et al.,
2007; Villemagne et al., 2008; Storandt et al., 2009). The most
logical explanation for these conﬂicting results is that different
studies include different blends of three different groups of cog-
nitively normal subjects: (i) normal cognition in the absence
of amyloid load and neurodegeneration; (ii) normal cognition in
the presence of some amyloid load and absence of neurodegen-
eration; and (iii) early cognitive decline in the presence of amyloid
load and neurodegeneration; thus leading to different conclusions.
In cognitively impaired subjects, both biomarkers of neuronal
pathology (CSF t-tau and structural MRI) and amyloid-b amyloid
load (CSF amyloid-b1–42) explained variability in general cognitive
performance (ADAS-Cog and MMSE). Most of the biomarkers of
Alzheimer’s disease correlated with the domain-speciﬁc scores as
well (Auditory–Verbal Learning Test, Boston naming, Trails B)
except for the lack of correlation between CSF amyloid-b1–42
with Boston naming and Trails B. Our ﬁnding of stronger correl-
ations between structural MRI and cognitive performance than
between CSF measures and cognitive measures is consistent with
Figure 3 Scatter plots of MMSE versus neuropathology markers: (A) CSF Amyloid-b1–42 (B) STAND-score (C) t-tau and (D) WMH.
Superimposed lines represent estimated mean MMSE as a function of the neuropathology marker for varying levels of AMNART. The red
line represents the 15th percentile of four errors on AMNART indicating a ‘good’ score, the blue line represents the median of 12 errors
indicating an ‘average’ score, and the green line represents the 85th percentile of 24 errors indicating a ‘bad’ score. The shaded region
about the blue line indicates a 95% bootstrap conﬁdence interval. These estimates come from penalized ordinal logistic regression models
as described in the methods. STAND = Structural Abnormality Index; WMH = white matter hyperintensity.
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Walhovd et al., 2010). This is also consistent with a recent path-
ology study that found that the effect of processing resources
(cognitive reserve) is slightly greater on the association between
neuronal pathology and cognition than plaques and cognition
(Boyle et al., 2008).
In this study we found that white matter hyperintensity did not
correlate with measures of general cognitive performance
(ADAS-Cog and MMSE) and memory domain scores (Auditory–
Verbal Learning Test) in clinically impaired subjects. However,
white matter hyperintensity correlated with domain scores for lan-
guage (Boston naming) and executive functioning (Trails B). Some
literature has shown that the degree of white matter hyperinten-
sity does not greatly impact cognitive performance in Alzheimer’s
disease (Wahlund et al., 1994; Hirono et al., 2000; Kono et al.,
2004) while others have found that the degree of white matter
hyperintensity does signiﬁcantly impact cognitive performance in
Alzheimer’s disease (DeCarli et al., 1995; Fazekas et al., 1996),
speciﬁcally deﬁcits in executive function and speed of cognitive
processing (Brickman et al. 2009a; Venkatraman et al. 2010).
These inconsistent results regarding correlations between white
matter hyperintensity and general cognition measures could be
because the effect of white matter hyperintensity on general cog-
nition (measured by MMSE and ADAS-Cog) might be small and
therefore differences in the population recruitment mechanisms
and patient numbers may have led to different conclusions.
Cognitive reserve and biomarkers of
Alzheimer’s disease pathology are
independent predictors of cognitive
performance
In cognitively normal subjects, since biomarkers of pathology do
not explain a signiﬁcant amount of variability in cognition, it is not
surprising that adjusting the correlation of AMNART with Boston
naming by the biomarkers does not appreciably affect the strength
of this association. In cognitively impaired subjects, both biomark-
ers of Alzheimer’s disease pathology and AMNART explained sig-
niﬁcant amount of variability in the measures of cognitive and
functional performance. The strength of the partial correlation be-
tween AMNART and the cognitive measures after adjusting for
each one of the biomarkers was similar to the strength of the
correlation before adjustment. In the reverse analysis shown in
Table 3, the strength of correlation between Alzheimer’s disease
biomarkers and cognitive measures was also similar before and
after adjustment for AMNART. These two results taken together
indicate that AMNART and biomarkers are independent predictors
of cognitive performance in Alzheimer’s disease.
The notion of an independent effect of AMNART on the rela-
tionship between cognition and biomarkers was further strength-
ened by our ordinal logistic regression ﬁndings. We found strong
evidence (P50.001) that AMNART and each biomarker variable
were additively associated with cognition as measured by MMSE
and found no evidence for interactions between AMNART and the
biomarkers (P40.59). We did not ﬁnd that the effect of
AMNART diminished with higher levels of pathology indicating
that an additive-protective effect of AMNART is constant across
the observed range of pathological severity. Though the models
summarized in Fig. 3 allow for an interaction between AMNART
and biomarkers, there was very little evidence of such. This, along
with the lack of rank correlation between AMNART and biomark-
ers, suggest that it is less an issue of being underpowered to
detect the interaction than that the data are consistent with a
process by which AMNART and pathology operate as largely in-
dependent but additive predictors. While the additive model is
supported by our data, at some point the aggregate effects of
neuropathology can be expected to dominate any neuroprotective
effects afforded by cognitive reserve. Although education has
been well accepted as a measure of cognitive reserve, in our pre-
liminary analysis we found that education did not correlate with
cognition after adjusting for AMNART. This suggests that
AMNART may be a more robust marker of the environmental
enrichment aspect of cognitive reserve than education. Rentz
et al. (2010) also found that education does not add any (signiﬁ-
cant) information in a model of amyloid and cognition that
included AMNART. This may be due to the fact that education
levels do not as effectively capture the environmental enrichment
afforded by life-long learning as effectively as AMNART. While
other markers of cognitive reserve exist, we have only presented
AMNART in this study. We also speciﬁcally tested MRI measures
of total intracranial volume as an independent measure of reserve
and found few associations with cognition and when present they
were very weak. The ‘Methods’ and ‘Results’ are presented in the
online Supplementary Material.
Implications for the relationship
between cognitive reserve, biomarkers
and cognition
The key observations in this study can be summarized using Fig. 4.
The cognitive decline or clinical function in mild cognitive impair-
ment and Alzheimer’s disease can be viewed as a downstream
process caused by an increasing neurodegenerative pathological
burden. If we plot the degree of abnormality in biomarkers and
clinical function/cognition as a function of disease stage, the effect
of cognitive reserve can be graphically conceptualized as moving
the cognition curves (Fig. 4B, indicates a ‘reference’ level of cog-
nitive reserve) relative to the biomarker curves which are located
upstream. Movement of cognition relative to biomarkers due to
the effect of cognitive reserve is to the left (Fig. 4A, less cognitive
reserve) or right (Fig. 4C, greater cognitive reserve). If i indicates
the distance between the biomarker curves and cognition for a
subject with average cognitive reserve at a ﬁxed point of cognition
where i denotes the different biomarkers that measure different
aspects of Alzheimer’s disease pathology (i denotes amyloid-b load
in the brain, t-tau or MRI); in this study we found evidence that
the distance between both the biomarker and cognition curve is
increased from i to (i +  CR+) for subjects with high cognitive
reserve and decreased from i to (i   CR) in subjects with
lower cognitive reserve, where  CR+ denotes the shift of the
curves in subjects with high cognitive reserve and  CR denotes
the shift in subjects with low cognitive reserve. In particular we
Cognitive reserve in Alzheimer’s disease Brain 2011: 134; 1479–1492 | 1487Figure 4 Model illustrating the independent effect of cognitive reserve on the relationship between biomarkers of pathology and cog-
nition in subjects with (A) low, (B) average and (C) high cognitive reserve. Clinical disease stage is indicated on the horizontal axis and the
magnitude of biomarker abnormalities (from normal to maximally abnormal) on the vertical axis. The biomarker curve labels are indicated
in A.I nA and C, the levels of amyloid-b are indicated by a square and the levels of atrophy are indicated by a circle at the point where
cognitively normal subjects progress to mild cognitive impairment. This illustrates that an equivalent clinical diagnostic threshold, subjects
with high cognitive reserve have greater biomarker abnormalities than low cognitive reserve subjects. MCI = mild cognitive impairment.
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the biomarker variable, i.e. the effect of cognitive reserve is addi-
tive; therefore, the distance moved by the cognition curve relative
to the biomarker curves would be the same irrespective of the
biomarker type. The evidence for this also comes from the fact
that the strength of correlation between cognition and AMNART
did not change much despite adjusting for each of the biomarkers.
A plausible model for the development of Alzheimer’s disease
posits that amyloid deposition occurs early in the process but by
itself does not directly cause clinical symptoms (Jack et al., 2009;
Mormino et al., 2009). On the other hand, impaired cognitive
performance is largely driven by neurodegeneration that may be
mediated by tau pathology. Based on this evidence, it has been
hypothesized that the Alzheimer’s disease pathological cascade is a
roughly two-stage process where amyloidosis and neuronal path-
ology (tauopathy, neuronal injury and neurodegeneration) are
largely sequential rather than concurrent processes (Ingelsson
et al., 2004; Jack et al., 2009, 2010). In this analysis we also
found support for this model since the correlation between MRI
and cognition was stronger than the correlation between CSF
amyloid-b1–42 indicating that amyloid-b levels in the brain are
saturating and MRI atrophy levels evolve simultaneously with
declining cognitive performance leading to a stronger correlation.
This directly translates into the fact that amyloid-b4MRI. The
primary observed effect of cognitive reserve was not to alter
amyloid-b  MRI, but to reduce or increase the distance between
the biomarker curves and cognitive performance from i to
(i +  CR+)o r( i   CR) based on the subject’s cognitive
reserve.
Evidence for the suggested model in
the literature
Two different approaches have been taken to study the effects of
cognitive reserve—studies that have investigated the effect of
cognitive reserve on the relationship between biomarkers and cog-
nition or the effect of cognitive reserve on declining cognition.
One class of articles provides strong evidence that biomarkers
are more abnormal at a given level of cognitive performance in
subjects with higher cognitive reserve when compared with sub-
jects with lower cognitive reserve. This has been shown to be true
for biomarkers of amyloid load (Kemppainen et al., 2008; Roe
et al., 2008a; Rentz et al., 2010), neurodegeneration and ﬁbre
tract integrity (Querbes et al., 2009; Teipel et al., 2009;
Piras et al., 2010), cerebral metabolism and perfusion (Alexander
et al., 1997; Scarmeas et al., 2003; Liao et al., 2005; Perneczky
et al., 2007; Garibotto et al., 2008; Hanyu et al., 2008;
Cohen et al., 2009) and white matter hyperintensity load
(Brickman et al., 2009b). Other reports support the cognitive re-
serve hypothesis by showing that high cognitive reserve delays the
onset of Alzheimer’s disease in the elderly (Hall et al., 2007;
Ngandu et al., 2007). There was evidence for this hypothesis in
our analysis where we found that better cognitive performance in
both cognitively normal and cognitively impaired subjects modest-
ly correlated with the AMNART errors after adjusting for the bio-
marker levels. This directly translates into the fact that at a given
level of cognitive performance the degree of biomarker abnormal-
ity is generally higher in subjects with greater cognitive reserve.
This can be illustrated as follows in Fig. 4: at the conceptual point
where a subject progresses from cognitively normal to mild cog-
nitive impairment in Fig. 4A and C, the levels of biomarker ab-
normality (square marker for amyloid-b levels and circle for
atrophy levels) are higher in Fig. 4C (high cognitive reserve)
when compared to Fig. 4A (low cognitive reserve) at the same
level of cognitive performance.
A second group of articles has investigated how cognitive re-
serve affects the rate of cognitive decline in Alzheimer’s disease.
The studies that have investigated the effect of cognitive reserve
on the rate of decline in Alzheimer’s disease (i.e. after onset of
dementia) support the hypothesis that although cognitive reserve
may delay the onset of dementia, after the onset of dementia the
rate of cognitive decline differs based on the subjects’ cognitive
reserve. Some authors have found that subjects with higher cog-
nitive reserve decline much faster (Unverzagt et al., 1998; Stern
et al., 1999; Andel et al., 2006; Hall et al., 2007; Bruandet et al.,
2008; Roselli et al., 2009) while others have found that subjects
with higher cognitive reserve decline more slowly (Fritsch et al.,
2001, 2002; Bennett et al., 2003; Manly et al., 2003; Le Carret
et al., 2005) when compared to subjects with low cognitive re-
serve. In addition, there was also evidence that the rate of decline
is the same in both the groups (Del Ser et al., 1999; Paradise
et al., 2009). We speculate that these inconsistent results may
be due to the fact that subjects were sampled at different levels
of biomarker abnormality along the cognition curve or at different
cognitive performance at baseline resulting in differences in the
observed rates. In response to increasing biomarker abnormality,
there is an early increase in the slope of cognitive decline as well
as an early saturation of the slope in subjects with low cognitive
reserve when compared to high cognitive reserve simply due to
the shift of the curves relative to the biomarker curves. This ob-
servation suggests the importance of measuring and adjusting for
the degree of biomarker abnormality in order to more accurately
understand the effect of cognitive reserve.
Limitations of this study
There were several limitations of this study. First, we used
AMNART which only measures one aspect of cognitive reserve,
namely the pre-morbid verbal intelligence. While AMNART might
not accurately capture all aspects of cognitive reserve, we believe
that it provides a reasonable approximation of the beneﬁcial effect
of education and life-long learning. A related issue is that the
particular aspect of cognitive reserve that AMNART is sensitive
to cannot be measured perfectly. Although AMNART has been
described as among the most reliable instruments in clinical use
(Strauss et al., 2006), and for that matter the biomarkers, are
subject to various degrees of measurement error that can affect
statistical inferences. Usually measurement error will attenuate as-
sociations although that is not always the case. Using the
simulation-extrapolation method, our ﬁndings were largely un-
affected by measurement error.
A second limitation is that ideally cognitive reserve metrics
should be obtained in middle age before any disease-related
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in cognitively normal subjects than either mild cognitive impair-
ment or Alzheimer’s disease, but error rates did not differ between
mild cognitive impairment and Alzheimer’s disease. We, therefore,
analysed cognitively normal subjects alone, and mild cognitive im-
pairment and Alzheimer’s disease as a single group. Rentz et al.
(2010) went a step further by adjusting AMNART by MMSE to
remove the confounding effect of cognitive performance on this
variable. However, if we were to apply this adjustment to remove
the effect of cognitive decline, we would be unable to observe a
relationship between the predictor variable (AMNART adjusted for
cognition) and the outcome variable (cognition) due to circularity
issues. And, one of our main objectives was to evaluate the effects
of AMNART and biomarkers independently on cognitive perform-
ance within clinical groups. Third, the Alzheimer’s Disease
Neuroimaging Initiative selection criteria excluded subjects with
signiﬁcant cerebrovascular disease (Hachinski score had to be
54). Therefore, the lack of a strong relationship between cogni-
tion and white matter hyperintensity in this cohort might partly be
attributed to the selection criteria. Fourth, the Alzheimer’s Disease
Neuroimaging Initiative cohort is not population based; control
and mild cognitive impairment subjects were subject to selection
criteria and demented subjects were limited to mild Alzheimer’s
disease. The recruitment mechanisms were those used for clinical
trials in Alzheimer’s disease and included memory clinics, patient
registries, public media campaigns and other forms of public ad-
vertisements. Consequently, inferences about the diagnostic sen-
sitivity, speciﬁcity etc., of biomarkers in the general population
cannot be drawn from Alzheimer’s Disease Neuroimaging
Initiative data. However, we believe that because the
Alzheimer’s Disease Neuroimaging Initiative incorporates patients
across a cognitive spectrum ranging from normal to mild
Alzheimer’s disease, biologically based conclusions concerning
the inﬂuence of cognitive reserve on the relationship between
Alzheimer’s disease biomarkers and cognition are valid. Last, the
cohort we used in this study does not have autopsy conﬁrmation,
which is a limitation of almost all such observational studies.
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